Cell Care Therapeutics is pioneering a new class of biologics derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). Their innovative secretome platform focuses on harnessing the signaling molecules produced by MSCs to enhance the health of blood vessels and surrounding tissues. This approach recognizes that the therapeutic benefits of MSCs primarily stem from their secretome rather than the cells themselves. The company is particularly focused on developing its lead product candidate, CCT-101, aimed at treating diabetic macular edema, a significant cause of vision loss among working-age adults.

The company positions itself as an industry leader in scaled secretome manufacturing, emphasizing the importance of this technology in addressing conditions like diabetic retinopathy, which affects approximately 120 million people globally. CCT-101 targets diabetic macular edema, a severe complication that impacts the central vision of around 24 million patients worldwide, including 1.7 million in the United States. By leveraging the therapeutic properties of MSC-derived secretome, Cell Care Therapeutics aims to provide effective treatments for chronic complications associated with diabetes, particularly those leading to severe vision loss.

United States

Cell Care Therapeutics is developing a new class of biologics that are derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). The company’s novel secretome platform harnesses the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. The company is developing its first product for the treatment of diabetic macular edema, the leading cause of vision loss in working age adults.

Cell Care Therapeutics

Company Details